This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The report by Comeau et al1 represents a landmark article in the 25-year evolution of cystic fibrosis (CF) newborn screening because it signifies an important shift in research to address questions about how we should achieve early diagnosis through trypsinogen/DNA analysis of neonatal blood specimens. The initial “should we” question has been investigated comprehensively for the past 2 decades, and a large body of supportive evidence has accumulated.2 Consequently, soon after the first CF screening workshop was organized in 1997 by the Centers for Disease Control and Prevention, the New England Newborn Screening Program (NENSP) began intensive preimplementation planning pursuant to the published recommendations.3 At the second Centers for Disease Control and Prevention workshop held in November 2003 (to be published), all the evidence accruing in favor of newborn screening for CF was reviewed, including potential cognitive benefits …
Reprint requests to (P.M.F.) University of Wisconsin Medical School, Room 1217 MSC, 1300 University Avenue, Madison, WI 53706. E-mail: pmfarrel{at}facstaff.wisc.edu
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
